|Bid||2.9000 x 800|
|Ask||2.9800 x 1800|
|Day's Range||2.8900 - 3.0400|
|52 Week Range||2.7000 - 8.7800|
|Beta (5Y Monthly)||1.97|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
The FDA has signed off Phase 1b/2 trial for Moleculin Biotech Inc's (NASDAQ: MBRX) Annamycin to treat soft tissue sarcoma lung metastases. Annamycin is the company's next-generation anthracycline that has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin. It has also demonstrated a lack of cardiotoxicity in recently conducted human clinical trials to treat acute myeloid leukemia (AML). Phase 1b portion of the trial will determine the maximum-tolerated dose and safety of Annamycin, and Phase 2 will explore the efficacy of Annamycin as a single agent. A maximum of 25 subjects will be enrolled at the RP2D to evaluate efficacy further. The company also expects a second Phase 1b/2 trial of Annamycin in sarcoma lung metastases to be initiated in 2021. Price Action: MBRX shares are up 0.69% at $3.64 during the market session on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaEyenovia Stock Shoots Higher on Positive MicroLine Data in Late-Stage Presbyopia StudyBristol Myers Licenses Xencor's Technology Platform to Extend Half-Life of COVID-19 Antibodies© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The FDA has granted Rare Pediatric Disease Designation to Moleculin Biotech Inc's (NASDAQ: MBRX) WP1066 to treat ependymoma. Ependymoma is a rare type of tumor in the brain or spinal cord and most often occurs in young children. The drug candidate currently received Orphan Drug Designation for WP1066 to treat brain tumors and Rare Pediatric tags for three other pediatric indications. Rare Pediatric Disease designation provides for the issuance of a priority review voucher following FDA approval. The voucher can be used for accelerated approval of a future application or sold to a third party. WP1066 is an immune/transcription modulator capable of directly inhibiting certain key oncogenic transcription factors, including the activated form of a protein known as STAT3. The activated form of STAT3, referred to as p-STAT3, is considered a master regulator of tumor activity. Price Action: MBRX shares are trading 6.96% higher at $3.87 on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaAstraZeneca's Tagrisso Scores Approval In China For Early Lung CancerUK Trial On Mix-Match COVID-19 Vaccines Expanded To Add Moderna, Novavax Shots© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.